Logo

CTMX

CytomX Therapeutics, Inc.

CTMX

CytomX Therapeutics, Inc. • NASDAQ
$4.28 ▲ 1.42% (+0.06)
Market Cap $724.90 M
52w High $4.62
52w Low $0.40
Dividend Yield 0%
P/E 14.27
Volume 694.26K
Outstanding Shares 169.37M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $5.963M ▼ $21.731M ▲ $-14.229M ▼ -238.621% ▼ $-0.09 ▼ $-14.037M ▼
Q2-2025 $18.658M ▼ $19.944M ▼ $-154K ▼ -0.825% ▼ $-0.001 ▼ $-939K ▼
Q1-2025 $50.917M ▲ $28.296M ▲ $23.525M ▲ 46.203% ▼ $0.27 ▲ $23.006M ▲
Q4-2024 $38.093M ▲ $20.414M ▼ $18.876M ▲ 49.552% ▲ $0.24 ▲ $18.092M ▲
Q3-2024 $33.432M $29.321M $5.736M 17.157% $0.067 $4.54M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $143.626M ▼ $158.254M ▼ $50.865M ▼ $107.389M ▼
Q2-2025 $158.087M ▲ $175.057M ▲ $55.147M ▼ $119.91M ▲
Q1-2025 $79.886M ▼ $98.497M ▼ $73.448M ▼ $25.049M ▲
Q4-2024 $100.623M ▼ $120.533M ▼ $120.989M ▼ $-456K ▲
Q3-2024 $117.588M $138.981M $162.433M $-23.452M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-14.229M ▼ $-15.548M ▲ $439K ▲ $253K ▼ $-14.856M ▼ $-15.421M ▲
Q2-2025 $-154K ▼ $-15.753M ▲ $-76.36M ▼ $93.55M ▲ $1.437M ▼ $-15.78M ▲
Q1-2025 $23.525M ▲ $-21.043M ▼ $30.596M ▲ $0 ▼ $9.553M ▲ $-21.162M ▼
Q4-2024 $18.876M ▲ $-19.908M ▲ $15.135M ▼ $2.249M ▲ $-2.524M ▲ $-19.988M ▲
Q3-2024 $5.736M $-20.729M $18.168M $0 $-2.561M $-20.748M

Five-Year Company Overview

Income Statement

Income Statement CytomX’s income statement shows a very small revenue base that moves around from year to year, likely tied to collaboration payments rather than product sales. After several years of sizable losses, the company recently swung to a modest accounting profit, but this looks fragile and heavily dependent on deal timing, not on a broad, stable business. Overall, the trend is from deep losses toward break-even, but on top of a narrow and volatile revenue foundation typical of a clinical-stage biotech with no approved products.

Balance Sheet

Balance Sheet The balance sheet is lean and has been shrinking over time, with total assets and the cash cushion both moving down from earlier levels. Debt is low, which is a plus, but equity has only recently climbed back to roughly neutral after being negative, suggesting past cumulative losses have largely eroded the capital base. In practical terms, CytomX now runs with limited balance-sheet buffer and is financially lighter than a few years ago, which makes future funding and partnership support important to watch.

Cash Flow

Cash Flow Despite the recent move to accounting profitability, the business is still burning cash. Operating cash flow has been consistently negative across the period, and free cash flow has tracked closely behind, indicating that cash out for research and operations exceeds what is coming in from partnerships and other sources. Capital spending is minimal, so the cash burn is really about R&D and overhead, not big investments in equipment. This pattern means the company remains dependent on raising capital or securing new collaboration payments over time.

Competitive Edge

Competitive Edge CytomX operates in a very crowded and fast-moving oncology space, but it does have a clear angle: conditionally activated biologics designed to be safer and more targeted. Its Probody platform is differentiated in concept and has been validated to some extent by partnerships with several large pharmaceutical companies. These alliances bring credibility and potential milestone revenue, but also mean CytomX must compete not only with external rivals but also for internal priority within its partners’ pipelines. The absence of approved products keeps its competitive position promising but unproven.

Innovation and R&D

Innovation and R&D Innovation is the core of CytomX’s story. The Probody platform is built to turn powerful drugs “on” only in the tumor environment, which could improve safety and unlock tough targets that are hard to hit with traditional antibodies. The pipeline spans antibody-drug conjugates, bispecifics, and cytokines, with a few notable internal programs and multiple partnered projects. This breadth and platform-based approach are clear strengths. However, the programs are still in clinical stages, so technical, regulatory, and timing risks are high, and ongoing R&D spending remains essential but cash-intensive.

Summary

CytomX combines a compelling scientific platform with a relatively fragile financial profile. On the positive side, it has moved from deep losses closer to break-even, carries little debt, and has attracted respected partners around a distinctive tumor-activated biologics approach. On the risk side, revenue is small and lumpy, cash burn continues, the asset base and cash reserves have shrunk, and there are no commercial products yet. The company’s future will largely hinge on clinical trial outcomes and the strength and timing of collaboration milestones or new deals, which introduces considerable uncertainty typical of early-stage biotech.

NEWS

November 25, 2025 · 8:00 AM UTC

CytomX Therapeutics to Present at Upcoming December Investor Conferences

Read more

November 13, 2025 · 8:00 AM UTC

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

Read more

November 6, 2025 · 4:10 PM UTC

CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 4, 2025 · 9:15 AM UTC

CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Read more

October 30, 2025 · 8:00 AM UTC

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

Read more